Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Trade Tensions, Market Volatility and Other Key Things to Watch this Week

Markets enter a critical week following Friday's dramatic selloff triggered by President Trump's threat of "massive tariffs" against China over tighter rare-earth export rules.

Barchart

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

Barchart

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Johnson Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.

Benzinga

$966 million fine: Johnson & Johnson held accountable for health risks tied to its baby powder

She trusted their baby powder for 80 years. It killed her.

We Got This Covered

FDA Expands Johnson & Johnson Ulcerative Colitis Drug Approval To Pediatric Patients

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson’s (NYSE:JNJ) Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kg.

Benzinga

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Options Corner: Despite Political Woes, Kenvue Can Still Make Tylenol Great Again

Amid a contentious political environment, consumer pharmaceutical firm Kenvue Inc (NYSE:KVUE) finds itself under a harsh spotlight. Specifically, its popular drug Tylenol has attracted the ire of the White House. Late last month, President Donald Trump stated on Truth Social that pregnant women shouldn't use Tylenol unless absolutely necessary. With…

Benzinga

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

MarketBeat

Coinbase To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

After badmouthing Tylenol, Trump makes deal with their rival company Pfizer

Weird how one happens before the other.

We Got This Covered

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Benzinga

What to Expect From Johnson & Johnson’s Q3 2025 Earnings Report

Johnson & Johnson is expected to release its fiscal third-quarter earnings next month, and analysts project a double-digit earnings rise.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Why This Dividend King Still Stands Tall

With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.

The Independent UK

Tylenol maker prepares for glut of lawsuits after Trump’s baseless warnings

‘Don’t take Tylenol,’ President Donald Trump repeatedly warned on Monday

Benzinga

This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Benzinga

Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors

Johnson Johnson (NYSE:JNJ) is reportedly halting international sales of its Linx Reflux Management System, a device used to treat chronic acid reflux.

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times UK

What Is the 'Tylenol Murders' and Why Does the Famous Analgesic Keep Getting Linked to Controversies?

More than 40 years after the unexpected deaths of seven people due to tainted medicine, Tylenol became the centre of attention again for a different reason.

Benzinga

Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients

Johnson Johnson (NYSE:JNJ) on Friday announced that an investigational immune-based induction regimen with Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).

Benzinga

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

Nanobiotix SA (NASDAQ:NBTX) announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.

Benzinga

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials

Johnson Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) on Wednesday released new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies of icotrokinra compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis.

MarketBeat

3 Dividend Stocks to Hold Through Market Volatility This Fall

Interest rate cuts may not decrease market volatility; discover three dividend stocks that can deliver stability, income, and growth during this fall

Benzinga

Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 Next

Despite ongoing legal battles related to its talc products, Johnson Johnson (NYSE:JNJ) stock has climbed over 23% year-to-date.

Benzinga

Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.